Hetero Healthcare to set up units in three states

PTI Mumbai | Updated on January 18, 2018 Published on July 31, 2016

Hetero Healthcare, a part of the Rs 7,500-crore Hetero Drugs, is setting up three units in Andhra Pradesh, Telangana and Assam to expand its formulations business in the country.

“We are setting up three new units at Andhra Pradesh, Telangana and Guwahati, Assam, to manufacture formulations for the domestic market. The Andhra unit will commence production in December, while Guwahati plant is almost 75 per cent ready and will be operational by March next year. Telangana unit will take some time,” Hetero Healthcare P K Hiradhar told PTI.

The company will manufacture injectables at the Andhra unit and tablets and capsules at Guwahati unit. These three units will add roughly around 20-25 per cent turnover to the company, he said, without divulging investment figures.

The firm has also lined up new molecules to expand its product portfolios in the Hepatitis, Oncology, and HIV segments, he added.

Hetero is one of the major global suppliers of APIs (including cytotoxics) to the pharmaceutical companies that manufacture formulations and new-generation products in India and abroad.

Hyderabad-based Hetero has over 25 manufacturing facilities located in India, China, Russia, Egypt, Mexico and Iran. Since 1993, the company has produced more than 300 APIs with over 60 of them receiving market approvals in the US and Europe. Additionally, the company produces bulk APIs for regulated and semi-regulated markets.

The company exports 60 per cent of its APIs and formulations to over 135 countries and it is a global market leader in HIV segment with 30 per cent global market share.

Nearly 90 per cent of its revenue comes from the international market, he said, adding that Hetero is the first company that launched Swine Flu drug (Oseltamivir with brand name Fluvir) in the domestic retail market.

The subsidiary firm, Hetero Healthcare, has strong product portfolios in Hepatitis, HIV and Oncology segments. Last year, Hetero had launched path-breaking Hepatitis C drugs Sofosbuvir along with other patent holders from Gileads.

Hetero HealthCare has also research & development facilities dedicated primarily to drug discovery.

Published on July 31, 2016
This article is closed for comments.
Please Email the Editor